Cochrane · systematic review · CD000052
Holding chambers (spacers) versus nebulisers for beta‐agonist treatment of acute asthma
Cates, CJ, Welsh, EJ, Rowe, BH · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library
AirwaysAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
10
current version
GRADE rated
10
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 2 · 20%Moderate 6 · 60%High 2 · 20%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Multiple treatment of beta₂‐agonist via spacer (chamber) compared to nebuliser for children with acute asthma
Population: children with acute asthma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Hospital admission Multiple treatment of beta₂‐agonist via spacer (chamber) vs nebuliser | RR 0.71 [0.47, 1.08] | 9 studies · 757 participants | Low Downgraded: imprecision |
Duration in emergency department (minutes) Multiple treatment of beta₂‐agonist via spacer (chamber) vs nebuliser | no estimate extracted | 3 studies · 396 participants | Moderate |
Final rise in FEV₁ (% predicted) Multiple treatment of beta₂‐agonist via spacer (chamber) vs nebuliser | no estimate extracted | 2 studies · 48 participants | Low Downgraded: imprecision |
Rise in pulse rate (% baseline) Multiple treatment of beta₂‐agonist via spacer (chamber) vs nebuliser | no estimate extracted | 9 studies · 670 participants | Moderate |
Number of participants developing tremor Multiple treatment of beta₂‐agonist via spacer (chamber) vs nebuliser | RR 0.64 [0.44, 0.95] | 4 studies · 254 participants | Moderate |
Multiple treatment of beta₂‐agonist via spacer (chamber) compared to nebuliser for adults with acute asthma
Population: Adults with acute asthma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Hospital admission Multiple treatment of beta₂‐agonist via spacer (chamber) vs nebuliser | RR 0.94 [0.61, 1.43] | 9 studies · 582 participants | Moderate Downgraded: risk of bias |
Duration in emergency department (minutes). Multiple treatment of beta₂‐agonist via spacer (chamber) vs nebuliser | no estimate extracted | 2 studies · 132 participants | Moderate |
Final rise in FEV₁(% predicted) Multiple treatment of beta₂‐agonist via spacer (chamber) vs nebuliser | no estimate extracted | 6 studies · 307 participants | High |
Rise in pulse rate (% baseline) Multiple treatment of beta₂‐agonist via spacer (chamber) vs nebuliser | no estimate extracted | 7 studies · 376 participants | High |
Number of participants developing tremor Multiple treatment of beta₂‐agonist via spacer (chamber) vs nebuliser | RR 1.12 [0.66, 1.9] | 4 studies · 234 participants | Moderate Downgraded: risk of bias |